论文部分内容阅读
[目的]探讨S-1联合奥沙利铂(SOX)方案围手术期化疗治疗进展期胃癌的有效性及安全性。[方法]回顾性分析54例接受围手术期化疗的进展期胃癌患者的病例资料。化疗方案为:替吉奥胶囊80mg/m2,d1~14,奥沙利铂130mg/m2,d1,静滴,每3周重复。评价化疗有效性及安全性,根据疗效分为临床有效组与临床无效组,观察比较两组的预后。[结果]本组患者术前化疗2~6个周期,平均(3.6±1.2)个周期。临床有效率为57.4%,疾病控制率为96.3%,R0切除率88.9%。3年生存率为61.5%,3年无进展生存率为55.3%。临床有效组(31例)和无效组(23例)的3年生存率分别为79.6%、38.6%(P=0.001);3年无进展生存率分别为70.7%、34.2%(P=0.009)。化疗期间常见的3级及以上血液毒性有血小板减少(14.8%)、白细胞减少(5.6%);常见的3级及以上非血液毒性有恶心呕吐(3.7%)、食欲不振(3.7%)。[结论]SOX方案围手术期化疗治疗进展期胃癌具有较高的有效率及较好的安全性,有效的围手术期化疗可改善进展期胃癌预后。
[Objective] To investigate the efficacy and safety of perioperative chemotherapy with S-1 combined with oxaliplatin (SOX) in the treatment of advanced gastric cancer. [Methods] A retrospective analysis of 54 cases of advanced gastric cancer patients undergoing perioperative chemotherapy case data. Chemotherapy program: for the geo capsule 80mg / m2, d1 ~ 14, oxaliplatin 130mg / m2, d1, intravenous infusion, repeated every 3 weeks. Evaluation of the effectiveness and safety of chemotherapy, according to the efficacy of clinical effective group and clinical invalid group, observed and compared the prognosis of the two groups. [Results] This group of patients preoperative chemotherapy 2 to 6 cycles, with an average of (3.6 ± 1.2) cycles. Clinical effective rate was 57.4%, disease control rate was 96.3%, R0 resection rate was 88.9%. 3-year survival rate was 61.5%, 3-year progression-free survival rate was 55.3%. The 3-year survival rates of the clinically effective group (31 cases) and the ineffective group (23 cases) were 79.6% and 38.6%, respectively (P = 0.001). The 3-year progression-free survival rates were 70.7% and 34.2% . Thrombocytopenia (14.8%) and leucopenia (5.6%) were common in patients with grade 3 and above hematologic toxicity during chemotherapy. Common grade 3 and above non-hematologic toxicities were nausea and vomiting (3.7%) and loss of appetite (3.7%). [Conclusion] Perioperative chemotherapy with SOX regimen in advanced gastric cancer has high efficiency and good safety. Effective perioperative chemotherapy can improve the prognosis of advanced gastric cancer.